UPDATED **EAST Search History** (INCLUDING INTERFERENCE) 10/500,839

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("20050020634").PN.	US-PGPUB	OR	OFF	2006/12/15 15:16
L2	596	549/283 OR 514/457	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/15 15:16
L3	226	L2 AND COUMARIN	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/15 15:17
L4	72	L3 AND (PLAQUE OR RESTENOSIS OR CHOLESTEROL OR ATHEROSCLEROSIS OR INFARCT OR INFARCTION OR HYPERLIPIDEMIA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/15 15:17
L5	5	L4 AND ACRYLIC	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/15 15:18

STN SEARCH TRANSCRIPT

10/500,839

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623zct

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 25	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 26	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 27	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:55:45 ON 15 DEC 2006

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'REGISTRY' ENTERED AT 14:58:49 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2006 HIGHEST RN 915690-78-7
DICTIONARY FILE UPDATES: 14 DEC 2006 HIGHEST RN 915690-78-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\PLAQUE REGRESSOR.str



chain nodes :
11 18 19 20 21 22 24 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 29 30 31 32 33 34
chain bonds :
8-11 9-25 10-12 14-18 18-19 19-20 20-21 20-22 25-26 26-27 26-28 27-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 29-30 29-34 30-31 31-32 32-33 33-34
exact/norm bonds :
8-11 20-21 20-22 26-27 26-28 27-29
exact bonds :
5-7 6-10 7-8 8-9 9-10 9-25 10-12 14-18 18-19 19-20 25-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 29-30
29-34 30-31 31-32 32-33 33-34
isolated ring systems :
containing 1 : 12 : 29 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR

X



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\PLAQUE REGRESSOR.str



chain nodes :
11 18 19 20 21 22 24 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 29 30 31 32 33 34
chain bonds :
8-11 9-25 10-12 14-18 18-19 19-20 20-21 20-22 25-26 26-27 26-28 27-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 29-30 29-34 30-31 31-32 32-33 33-34
exact/norm bonds :
8-11 20-21 20-22 26-27 26-28 27-29
exact bonds :
5-7 6-10 7-8 8-9 9-10 9-25 10-12 14-18 18-19 19-20 25-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 29-30
29-34 30-31 31-32 32-33 33-34

```
isolated ring systems :
containing 1 : 12 : 29 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:CLASS
20:CLASS  21:CLASS  22:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom



L2      STRUCTURE UPLOADED

=> S L2
SAMPLE SEARCH INITIATED 15:01:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               1 TO       80

L3            1 SEA SSS SAM L2

=> S L2 SSS FULL
FULL SEARCH INITIATED 15:01:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       86 TO ITERATE

100.0% PROCESSED       86 ITERATIONS                                49 ANSWERS
SEARCH TIME: 00.00.01

L4           49 SEA SSS FUL L2

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   168.70     169.75

FILE 'CAPLUS' ENTERED AT 15:02:03 ON 15 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Dec 2006  VOL 145 ISS 26
FILE LAST UPDATED: 14 Dec 2006  (20061214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:
```

http://www.cas.org/infopolicy.html

=> S L4
L5 4 L4

=> D 1-4 IBIB ABS HITSTR

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:979634 CAPLUS
DOCUMENT NUMBER: 143:266819
TITLE: Preparation of coumarin-acrylate derivatives and solvates thereof as ACAT inhibitors
INVENTOR(S): Marui, Shogo; Ogino, Masaki; Tawada, Hiroyuki; Yabe, Osamu
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082879	A1	20050909	WO 2005-JP3838	20050301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005217335	A1	20050909	AU 2005-217335	20050301
CA 2557162	AA	20050909	CA 2005-2557162	20050301
EP 1720850	A1	20061115	EP 2005-720110	20050301
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

PRIORITY APPLN. INFO.: JP 2004-57920 A 20040302
WO 2005-JP3838 W 20050301

OTHER SOURCE(S): MARPAT 143:266819
GI



I



II

AB Alkaline earth metal or organic amine salts of I [R1-2 = H, halo, alkyl; A, B = Ph ring; R = carboxy, alkyl] are prepared For instance, monocalcium bis[(E)-II]•trihydrate (III) is prepared in 8 steps from 3-chloro-4-methylanisole, 3-bromobenzoyl chloride, Et succinic chloride, 2-amino-5-fluorobenzotrifluoride and Bu acrylate. III has an IC50 = 1956 nM for cholesterol ester synthetase (ACAT). Alkaline earth/organic amine salts of I are useful for the treatment of atherosclerosis.

IT 863983-72-6P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(X-ray powder diffraction provided; preparation of coumarin-acrylate derivs. and solvates thereof as ACAT inhibitors)

RN 863983-72-6 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, calcium salt (2:1), trihydrate, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



●1/2 Ca

PAGE 2-A

●3/2 H_2O

IT 434333-03-6P 863983-69-1P 863983-71-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of coumarin-acrylate derivs. and solvates thereof as ACAT inhibitors)

RN 434333-03-6 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863983-69-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)-, compd. with 2-propanone (10:9) (9CI) (CA INDEX NAME)

CM 1

CRN 434333-03-6
CMF C28 H18 Cl F4 N O5

Double bond geometry as shown.



CM 2

CRN 67-64-1
CMF C3 H6 O



RN 863983-71-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, monosodium salt, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

IT 863983-74-8P 863983-76-0P 863983-79-3P
863983-85-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of coumarin-acrylate derivs. and solvates thereof as ACAT inhibitors)

RN 863983-74-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, monoammonium salt, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● NH_3

RN 863983-76-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 434333-03-6
CMF C28 H18 Cl F4 N O5

Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 863983-79-3 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 434333-03-6
CMF C28 H18 Cl F4 N O5

Double bond geometry as shown.



CM 2

CRN 111-42-2
CMF C4 H11 N O2

RN 863983-85-1 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-methyl-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, calcium salt (2:1), (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●1/2 Ca

IT 863983-89-5P 863983-97-5P 863983-98-6P
863984-01-4P 863984-02-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of coumarin-acrylate derivs. and solvates thereof as ACAT inhibitors)

RN 863983-89-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, butyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863983-97-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-5-hydroxy-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863983-98-6 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-5-hydroxy-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863984-01-4 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-hydroxy-6-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863984-02-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-hydroxy-6-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:570975 CAPLUS
DOCUMENT NUMBER: 139:133469
TITLE: Preparation of coumarin derivatives as lipid-rich plaque inhibitors and ACAT inhibitors
INVENTOR(S): Terashita, Zenichi; Nakamura, Masahira; Marui, Shogo; Ogino, Masaki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059900	A1	20030724	WO 2003-JP112	20030109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2472419	AA	20030724	CA 2003-2472419		20030109
AU 2003202488	A1	20030730	AU 2003-202488		20030109
EP 1471064	A1	20041027	EP 2003-701037		20030109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1615305	A	20050511	CN 2003-802170		20030109
NZ 533893	A	20060630	NZ 2003-533893		20030109
JP 2003267965	A2	20030925	JP 2003-3999		20030110
US 2005020634	A1	20050127	US 2004-500839		20040707
NO 2004003349	A	20041005	NO 2004-3349		20040810
PRIORITY APPLN. INFO.:			JP 2002-4359	A	20020111
			WO 2003-JP112	W	20030109

OTHER SOURCE(S): MARPAT 139:133469

GI



I

AB The title compds. I [R1 and R2 are each hydrogen, halogeno, etc., or R1 and R2 together with the carbon atoms adjacent thereto may form an optionally substituted carbocyle, etc.; A is a benzene ring which may be further substituted; B is an aromatic ring which may be substituted; X is a bond or a spacer whose main chain has 1 to 6 atoms; Y is carboxyl which may be esterified, carbamoyl which may be substituted, cyano, etc.] are prepared Compds. of this invention in vitro showed IC50 values of 0.42 μM to 1.22 μM against ACAT. Formulations are given.

IT 566945-35-5P 566945-36-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of coumarin derivs. as lipid-rich plaque inhibitors and ACAT inhibitors)

RN 566945-35-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[6-[(acetyloxy)methyl]-7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-36-6 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-(hydroxymethyl)-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 566944-28-3P 566944-29-4P 566944-30-7P
566944-31-8P 566944-32-9P 566944-40-9P
566944-41-0P 566944-42-1P 566944-43-2P
566944-44-3P 566944-51-2P 566944-53-4P
566944-54-5P 566944-55-6P 566944-64-7P
566944-77-2P 566944-90-9P 566944-93-2P
566944-94-3P 566944-95-4P 566945-07-1P
566945-08-2P 566945-25-3P 566945-26-4P
566945-29-7P 566945-30-0P 566945-53-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of coumarin derivs. as lipid-rich plaque inhibitors and ACAT inhibitors)

RN 566944-28-3 CAPLUS
CN 2-Propenoic acid, 3-[5-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]-2-fluorophenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-29-4 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-methyl-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-30-7 CAPLUS
CN 2-Propenoic acid, 3-[3-[6-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-7-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-31-8 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-fluoro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-32-9 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-40-9 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-methyl-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-41-0 CAPLUS
CN 2-Propenoic acid, 3-[3-[6-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-7-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-42-1 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-fluoro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-43-2 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-44-3 CAPLUS
CN 2-Propenoic acid, 3-[5-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]-2-fluorophenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-51-2 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-53-4 CAPLUS
CN 2-Propenoic acid, 3-[3-[3-[2-[[2,6-bis(1-methylethyl)phenyl]amino]-2-oxoethyl]-7-chloro-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-54-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-methyl-2-oxo-3-[2-oxo-2-[(2,4,6-trifluorophenyl)amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-55-6 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[(2,6-dimethoxyphenyl)amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-64-7 CAPLUS
CN 2-Butenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-77-2 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-2-methyl-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-90-9 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-2-oxo-3-[2-oxo-2-[[2-(trifluoromethyl)phenyl]amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-93-2 CAPLUS
CN 2-Propenoic acid, 3-[3-[3-[2-[[2,6-bis(1-methylethyl)phenyl]amino]-2-oxoethyl]-7-chloro-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-94-3 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-6-methyl-2-oxo-3-[2-oxo-2-[(2,4,6-trifluorophenyl)amino]ethyl]-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566944-95-4 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[(2,6-dimethoxyphenyl)amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-07-1 CAPLUS
CN 2-Butenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-08-2 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-25-3 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-6-[(4-phenyl-1-piperazinyl)methyl]-2H-1-benzopyran-4-yl]phenyl]-, butyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-26-4 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-6-[(4-phenyl-1-piperazinyl)methyl]-2H-1-benzopyran-4-yl]phenyl]-, butyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-29-7 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-6-[(4-phenyl-1-piperazinyl)methyl]-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-30-0 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-2-oxo-6-[(4-phenyl-1-piperazinyl)methyl]-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 566945-53-7 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, 2-(diethylamino)ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 434333-02-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of coumarin derivs. as lipid-rich plaque inhibitors and ACAT inhibitors)
RN 434333-02-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:465845 CAPLUS
DOCUMENT NUMBER: 137:24354
TITLE: Medicinal compositions containing lipid-rich plaque retracting agents having improved water-solubility
INVENTOR(S): Akiyama, Yohko; Bando, Hiroto; Matsumoto, Yukihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047723	A1	20020620	WO 2001-JP10829	20011211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002021116	A5	20020624	AU 2002-21116	20011211
JP 2002241267	A2	20020828	JP 2001-377069	20011211
PRIORITY APPLN. INFO.:			JP 2000-375604 A	20001211
			WO 2001-JP10829 W	20011211

OTHER SOURCE(S): MARPAT 137:24354

AB Disclosed are solid dispersions containing water-insol. or hardly water-soluble lipid-rich plaque retracting substance and a hydrophilic polymer. These dispersions have been improved in the solubility of the lipid rich plaque retracting substance, oral absorbability and absorbability in blood. A lipid-rich plaque retracting agent 2-[7-chloro-2-oxo-4-phenyl-6-[(4-phenyl-1-piperazinyl)methyl]-2H-chromene-3-yl]-N-[4-chloro-2-(trifluoromethyl)phenyl]acetamide was prepared, and combined with hydroxypropyl Me cellulose phthalate and lactose to obtain a solid dispersion. The obtained solid dispersion showed improved bioavailability as compared with that of the compound itself when it orally administered to rats.

IT 434333-16-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of solid dispersions containing water-insol. or hardly water-soluble
lipid-rich plaque retracting substances and hydrophilic polymers)

RN 434333-16-1 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 391687-74-4P 391687-75-5P 391688-14-5P
391688-15-6P 391688-17-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(solid dispersions containing water-insol. or hardly water-soluble lipid-rich
plaque retracting substances and hydrophilic polymers)

RN 391687-74-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 391687-75-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 391688-14-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 391688-15-6 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 391688-17-8 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 434333-02-5 434333-03-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dispersions containing water-insol. or hardly water-soluble lipid-rich
plaque retracting substances and hydrophilic polymers)
RN 434333-02-5 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 434333-03-6 CAPLUS
CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:72079 CAPLUS
DOCUMENT NUMBER: 136:134672
TITLE: Preparation of benzopyranone derivatives as HMG-CoA reductase inhibitors useful as lipid-rich plaque regression agents
INVENTOR(S): Terashita, Zenichi; Nakamura, Masahira; Marui, Shogo; Ogino, Masaki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006264	A1	20020124	WO 2001-JP6070	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001069516	A5	20020130	AU 2001-69516	20010713
JP 2002255808	A2	20020911	JP 2001-213279	20010713
CA 2429008	AA	20030109	CA 2001-2429008	20010713
EP 1302470	A1	20030416	EP 2001-947999	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200302825	A2	20031229	HU 2003-2825	20010713
NZ 523550	A	20040528	NZ 2001-523550	20010713
NO 2003000138	A	20030110	NO 2003-138	20030110
US 2003232809	A1	20031218	US 2003-332632	20030110
US 6974806	B2	20051213		
US 2006035865	A1	20060216	US 2005-212800	20050826
PRIORITY APPLN. INFO.:			JP 2000-212611 A	20000713
			JP 2000-395079 A	20001226
			WO 2001-JP6070 W	20010713

OTHER SOURCE(S): CASREACT 136:134672; MARPAT 136:134672

GI



I



II

AB Title compds. [I; A = cyclic hydrocarbon; B = heterocycle; X, Y each independently = NR1; R1 = hydrocarbyl; D = C1-3 alkylene; E = NH; G = free valency; Ar = aryl; D, R4 together with constituent atoms of B = ring] and salts thereof , are prepared as lipid-rich plaque regression agents and formulation discussed. Thus, the title compound II was prepared and in vivo biol. tested.

IT 391687-75-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzopyranone derivs. as HMG-CoA reductase inhibitors useful as lipid-rich plaque regression agents)

RN 391687-75-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 391687-74-4P 391688-14-5P 391688-15-6P 391688-17-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzopyranone derivs. as HMG-CoA reductase inhibitors useful as lipid-rich plaque regression agents)

RN 391687-74-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 391688-14-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 391688-15-6 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 391688-17-8 CAPLUS

CN 2-Propenoic acid, 3-[3-[7-chloro-3-[2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-6-methyl-2-oxo-2H-1-benzopyran-4-yl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOG HOLD

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.36	191.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:03:02 ON 15 DEC 2006